LENZ Therapeutics, Inc. (LENZ) Wednesday announced positive results from the Phase 3 CLARITY study of its two drug candidates LNZ100 and LNZ101, for the treatment of presbyopia, the loss of eye's ability to see nearby objects. The company's shares were up more than 20 percent in pre-market at $26.10.
In the Phase 3 CLARITY 1 and 2 trials, the primary endpoint was met after 71 percent of participants dosed with LNZ100 achieved three-lines or greater improvement at 3 hours.
The company has chosen LNZ100 as its lead drug candidate. While LNZ101 also showed similar results, it was not superior to LNZ100.
LENZ Therapeutics plans to submit a New Drug Application for LNZ100 in mid-2024.
Shares of LENZ Therapeutics had closed at $21.01 on Tuesday. The stock has been trading in the range of $2.01 - $24.05 in the last 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.